17,192 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Grantham Mayo Van Otterloo & Co. LLC

Grantham Mayo Van Otterloo & Co. LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, Holdings Channel.com reports. The fund acquired 17,192 shares of the company’s stock, valued at approximately $5,712,000.

A number of other institutional investors have also recently modified their holdings of MEDP. Pallas Capital Advisors LLC increased its position in shares of Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares during the period. Barclays PLC grew its stake in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after buying an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after buying an additional 844 shares during the period. Janus Henderson Group PLC raised its position in shares of Medpace by 10.0% in the 3rd quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock valued at $14,722,000 after buying an additional 4,023 shares in the last quarter. Finally, SYM FINANCIAL Corp bought a new stake in shares of Medpace during the 4th quarter worth approximately $320,000. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective for the company. Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $376.30.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $287.11 on Monday. The company has a 50 day simple moving average of $331.56 and a 200 day simple moving average of $337.32. Medpace Holdings, Inc. has a 1 year low of $282.42 and a 1 year high of $459.77. The firm has a market cap of $8.75 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.